TY - JOUR KW - Adolescent KW - Adult KW - Aged KW - Child KW - Drug Administration Schedule KW - Drug Therapy, Combination KW - Female KW - Humans KW - Leprostatic Agents KW - leprosy KW - Male KW - Middle Aged KW - Treatment Outcome AU - Sales A AU - Sabroza PC AU - Costa Nery JA AU - Duppre NC AU - Sarno E AB -

A comparative study was made of the initial and final bacterial indices (BIs) of 213 MB leprosy patients who had been administered 12-dose (Group 1/128 patients) and 24-dose (Group 2/85 patients) World Health Organization multi-drug therapy to measure the effectiveness of both treatment regimens. All patients were evaluated at the beginning of treatment, at 12 months, and again after 24 months had elapsed. Decline in BI values and average BIs at 24 months were found to be similar for both groups. Moreover, no statistical difference between the two treatment regimens was found in the frequency rate of reaction.

BT - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association C1 - http://www.ncbi.nlm.nih.gov/pubmed/15485290?dopt=Abstract DA - 2004 Sep DO - 10.1489/0020-7349(2004)72<320:ACSBAD>2.0.CO;2 IS - 3 J2 - Int. J. Lepr. Other Mycobact. Dis. LA - eng N2 -

A comparative study was made of the initial and final bacterial indices (BIs) of 213 MB leprosy patients who had been administered 12-dose (Group 1/128 patients) and 24-dose (Group 2/85 patients) World Health Organization multi-drug therapy to measure the effectiveness of both treatment regimens. All patients were evaluated at the beginning of treatment, at 12 months, and again after 24 months had elapsed. Decline in BI values and average BIs at 24 months were found to be similar for both groups. Moreover, no statistical difference between the two treatment regimens was found in the frequency rate of reaction.

PY - 2004 SP - 320 EP - 3 T2 - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association TI - A comparative study between 12 and 24-dose therapeutic regimens for multibacillary leprosy patients. UR - http://ila.ilsl.br/pdfs/v72n3a09.pdf VL - 72 SN - 0148-916X ER -